Premium
Developmental Pharmacogenetics: A General Paradigm for Application to Neonatal Pharmacology and Toxicology
Author(s) -
Leeder J S
Publication year - 2009
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2009.195
Subject(s) - clinical pharmacology , pharmacogenetics , pharmacogenomics , medicine , drug reaction , drug , in utero , population , pharmacology , intensive care medicine , bioinformatics , toxicology , fetus , biology , genetics , pregnancy , environmental health , genotype , gene
Therapy in newborn infants presents unique challenges. The consequences of exposure of the fetus to medications and environmental contaminants in utero (following the mother's exposure to these) may present, in the newborn, as congenital malformations or adverse drug reactions or have unknown long‐term consequences. Risk is not uniformly distributed across a population. Rather, pharmacogenomic principles assert that an individual's unique clinical, genomic, and environmental information can be used to accurately predict predisposition to risk. The challenge is to identify the specific factors—genetic and nongenetic—that contribute to increased risk. Clinical Pharmacology & Therapeutics (2009) 86 6, 634–643. doi: 10.1038/clpt.2009.151